DMRA compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

DMRADamora Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

DMRADamora Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only DMRA 3

—Paragonunlistedsupplier

—Pre-Acquisition Damoraunlistedsupplier

—Bridge Medicinesunlistedsupplier

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

DMRADamora Therapeutics, Inc.

21.84▼−4.80%· post 21.54

Mkt cap$1.4BRevenue—Revenue—

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

ClosedNov 5 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 5 '26

DMRADamora Therapeutics, Inc.

LLYELI Lilly & Co

21.84▼−4.80%post 21.54

Price

1,371.32▼−3.29%post 1,363.77

$1.4B

Mkt cap

$1.2T

—

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

DMRA21.84▼−4.80%vsLLY1,371.32▼−3.29%ClosedNov 5 '26